Singapur - inglise - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - aflibercept - injection, solution - 2.0mg/50mcl - aflibercept 2.0mg/50mcl

Singapur - inglise - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - aflibercept - injection, solution - 2.0mg/50mcl - aflibercept 2.0mg/50mcl

Euroopa Liit - inglise - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - ranibizumab 10 mg/ml - 10 mg/ml

Iisrael - inglise - Ministry of Health

novartis israel ltd - ranibizumab - solution for injection - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd). treatment of adult patients with visual impairment due to diabetic macular oedema (dme) . the treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (rvo). the treatment of visual impaiment due to choroidal neovascularization (cnv) . lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.the treatment of proliferative diabetic retinopathy (pdr)

Euroopa Liit - inglise - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Euroopa Liit - inglise - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - lucentis is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to choroidal neovascularisation (cnv)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)

Euroopa Liit - inglise - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanib - wet macular degeneration - ophthalmologicals - macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (amd).

Euroopa Liit - inglise - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (amd) with predominantly classic subfoveal choroidal neovascularisation (cnv) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

Kanada - inglise - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous